vs
PUMA BIOTECHNOLOGY, INC.（PBYI）与TRANSCAT INC（TRNS）财务数据对比。点击上方公司名可切换其他公司
TRANSCAT INC的季度营收约是PUMA BIOTECHNOLOGY, INC.的1.1倍（$83.9M vs $75.5M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs 25.6%），PUMA BIOTECHNOLOGY, INC.自由现金流更多（$14.4M vs $9.5M），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs 8.7%）
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
Transcat Inc是一家提供校准与计量合规解决方案、经销专业测试测量仪器的企业，核心服务领域覆盖生命科学、航空航天、工业制造、能源公用事业等，主要业务遍布美国和加拿大，帮助客户满足合规及运营精度要求。
PBYI vs TRNS — 直观对比
营收规模更大
TRNS
是对方的1.1倍
$75.5M
营收增速更快
PBYI
高出2.1%
25.6%
自由现金流更多
PBYI
多$4.9M
$9.5M
两年增速更快
PBYI
近两年复合增速
8.7%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $75.5M | $83.9M |
| 净利润 | — | $-1.1M |
| 毛利率 | 69.3% | 30.1% |
| 营业利润率 | 22.7% | 0.1% |
| 净利率 | — | -1.3% |
| 营收同比 | 27.7% | 25.6% |
| 净利润同比 | — | -146.7% |
| 每股收益（稀释后） | $0.26 | $-0.12 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PBYITRNS
| Q4 25 | $75.5M | $83.9M | ||
| Q3 25 | $54.5M | $82.3M | ||
| Q2 25 | $52.4M | $76.4M | ||
| Q1 25 | $46.0M | $77.1M | ||
| Q4 24 | $59.1M | $66.8M | ||
| Q3 24 | $80.5M | $67.8M | ||
| Q2 24 | $47.1M | $66.7M | ||
| Q1 24 | $43.8M | $70.9M |
净利润PBYITRNS
| Q4 25 | — | $-1.1M | ||
| Q3 25 | $8.8M | $1.3M | ||
| Q2 25 | $5.9M | $3.3M | ||
| Q1 25 | $3.0M | $4.5M | ||
| Q4 24 | — | $2.4M | ||
| Q3 24 | $20.3M | $3.3M | ||
| Q2 24 | $-4.5M | $4.4M | ||
| Q1 24 | $-4.8M | $6.9M |
毛利率PBYITRNS
| Q4 25 | 69.3% | 30.1% | ||
| Q3 25 | 77.7% | 32.5% | ||
| Q2 25 | 76.5% | 33.8% | ||
| Q1 25 | 77.1% | 33.6% | ||
| Q4 24 | 76.4% | 29.5% | ||
| Q3 24 | 63.9% | 31.3% | ||
| Q2 24 | 77.4% | 34.0% | ||
| Q1 24 | 75.5% | 33.9% |
营业利润率PBYITRNS
| Q4 25 | 22.7% | 0.1% | ||
| Q3 25 | 17.6% | 4.3% | ||
| Q2 25 | 12.7% | 7.0% | ||
| Q1 25 | 8.7% | 9.0% | ||
| Q4 24 | 22.6% | 3.1% | ||
| Q3 24 | 27.4% | 5.5% | ||
| Q2 24 | -4.6% | 7.6% | ||
| Q1 24 | -5.3% | 13.0% |
净利率PBYITRNS
| Q4 25 | — | -1.3% | ||
| Q3 25 | 16.2% | 1.5% | ||
| Q2 25 | 11.2% | 4.3% | ||
| Q1 25 | 6.5% | 5.8% | ||
| Q4 24 | — | 3.5% | ||
| Q3 24 | 25.2% | 4.8% | ||
| Q2 24 | -9.6% | 6.6% | ||
| Q1 24 | -11.0% | 9.7% |
每股收益（稀释后）PBYITRNS
| Q4 25 | $0.26 | $-0.12 | ||
| Q3 25 | $0.17 | $0.14 | ||
| Q2 25 | $0.12 | $0.35 | ||
| Q1 25 | $0.06 | $0.49 | ||
| Q4 24 | $0.40 | $0.25 | ||
| Q3 24 | $0.41 | $0.35 | ||
| Q2 24 | $-0.09 | $0.48 | ||
| Q1 24 | $-0.10 | $0.81 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $97.5M | $3.5M |
| 总债务越低越好 | $22.7M | — |
| 股东权益账面价值 | $130.3M | $296.8M |
| 总资产 | $216.3M | $472.9M |
| 负债/权益比越低杠杆越低 | 0.17× | — |
8季度趋势，按日历期对齐
现金及短期投资PBYITRNS
| Q4 25 | $97.5M | $3.5M | ||
| Q3 25 | $94.4M | $5.1M | ||
| Q2 25 | $96.0M | $1.9M | ||
| Q1 25 | $93.2M | $1.5M | ||
| Q4 24 | $101.0M | $4.6M | ||
| Q3 24 | $96.7M | $23.8M | ||
| Q2 24 | $96.8M | $22.7M | ||
| Q1 24 | $107.2M | $35.2M |
总债务PBYITRNS
| Q4 25 | $22.7M | — | ||
| Q3 25 | $34.0M | — | ||
| Q2 25 | $45.3M | — | ||
| Q1 25 | $56.7M | — | ||
| Q4 24 | $68.0M | — | ||
| Q3 24 | $79.3M | — | ||
| Q2 24 | $90.7M | — | ||
| Q1 24 | $102.0M | — |
股东权益PBYITRNS
| Q4 25 | $130.3M | $296.8M | ||
| Q3 25 | $115.3M | $295.4M | ||
| Q2 25 | $104.7M | $292.5M | ||
| Q1 25 | $97.1M | $286.9M | ||
| Q4 24 | $92.1M | $281.1M | ||
| Q3 24 | $71.1M | $268.8M | ||
| Q2 24 | $48.5M | $262.3M | ||
| Q1 24 | $51.0M | $225.2M |
总资产PBYITRNS
| Q4 25 | $216.3M | $472.9M | ||
| Q3 25 | $202.9M | $484.9M | ||
| Q2 25 | $194.9M | $392.5M | ||
| Q1 25 | $196.2M | $385.2M | ||
| Q4 24 | $213.3M | $386.0M | ||
| Q3 24 | $220.7M | $323.6M | ||
| Q2 24 | $205.0M | $323.7M | ||
| Q1 24 | $214.1M | $287.6M |
负债/权益比PBYITRNS
| Q4 25 | 0.17× | — | ||
| Q3 25 | 0.30× | — | ||
| Q2 25 | 0.43× | — | ||
| Q1 25 | 0.58× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 1.12× | — | ||
| Q2 24 | 1.87× | — | ||
| Q1 24 | 2.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.4M | $12.1M |
| 自由现金流经营现金流 - 资本支出 | $14.4M | $9.5M |
| 自由现金流率自由现金流/营收 | 19.1% | 11.3% |
| 资本支出强度资本支出/营收 | 0.0% | 3.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $41.7M | $24.9M |
8季度趋势，按日历期对齐
经营现金流PBYITRNS
| Q4 25 | $14.4M | $12.1M | ||
| Q3 25 | $9.7M | $12.9M | ||
| Q2 25 | $14.1M | $3.6M | ||
| Q1 25 | $3.6M | $10.6M | ||
| Q4 24 | $15.6M | $12.6M | ||
| Q3 24 | $11.0M | $6.8M | ||
| Q2 24 | $1.0M | $8.9M | ||
| Q1 24 | $11.2M | $5.7M |
自由现金流PBYITRNS
| Q4 25 | $14.4M | $9.5M | ||
| Q3 25 | $9.7M | $8.4M | ||
| Q2 25 | $14.1M | $-975.0K | ||
| Q1 25 | $3.6M | $7.9M | ||
| Q4 24 | $15.6M | $9.7M | ||
| Q3 24 | $11.0M | $2.9M | ||
| Q2 24 | $1.0M | $5.3M | ||
| Q1 24 | — | $1.5M |
自由现金流率PBYITRNS
| Q4 25 | 19.1% | 11.3% | ||
| Q3 25 | 17.7% | 10.3% | ||
| Q2 25 | 26.8% | -1.3% | ||
| Q1 25 | 7.7% | 10.3% | ||
| Q4 24 | 26.4% | 14.6% | ||
| Q3 24 | 13.7% | 4.2% | ||
| Q2 24 | 2.1% | 7.9% | ||
| Q1 24 | — | 2.2% |
资本支出强度PBYITRNS
| Q4 25 | 0.0% | 3.2% | ||
| Q3 25 | 0.0% | 5.4% | ||
| Q2 25 | 0.0% | 6.0% | ||
| Q1 25 | 0.1% | 3.5% | ||
| Q4 24 | 0.0% | 4.3% | ||
| Q3 24 | 0.0% | 5.8% | ||
| Q2 24 | 0.0% | 5.5% | ||
| Q1 24 | 0.0% | 5.9% |
现金转化率PBYITRNS
| Q4 25 | — | — | ||
| Q3 25 | 1.10× | 10.15× | ||
| Q2 25 | 2.41× | 1.11× | ||
| Q1 25 | 1.21× | 2.38× | ||
| Q4 24 | — | 5.34× | ||
| Q3 24 | 0.54× | 2.08× | ||
| Q2 24 | — | 2.02× | ||
| Q1 24 | — | 0.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
